MedPath

Center for Research in Security Prices, LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

866

Active:71
Completed:440

Trial Phases

6 Phases

Early Phase 1:28
Phase 1:111
Phase 2:174
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (720 trials with phase data)• Click on a phase to view related trials

Not Applicable
328 (45.6%)
Phase 2
174 (24.2%)
Phase 1
111 (15.4%)
Phase 4
62 (8.6%)
Early Phase 1
28 (3.9%)
Phase 3
17 (2.4%)

SGLT2i in Kidney Stones

Not Applicable
Not yet recruiting
Conditions
Kidney Stones
Interventions
First Posted Date
2025-07-08
Last Posted Date
2025-07-08
Lead Sponsor
University of Chicago
Target Recruit Count
32
Registration Number
NCT07055282
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

Continuous Glucose Monitoring to Detect Postpartum Dysglycemia in Patients With Gestational Diabetes

Not Applicable
Not yet recruiting
Conditions
Gestational Diabetes
First Posted Date
2025-06-24
Last Posted Date
2025-06-24
Lead Sponsor
University of Chicago
Target Recruit Count
50
Registration Number
NCT07034261

Mood Effects of Serotonin Agonists: Depression

Early Phase 1
Recruiting
Conditions
LSD
Major Depressive Disorder
Depression
Interventions
Drug: Placebo
First Posted Date
2025-06-12
Last Posted Date
2025-07-03
Lead Sponsor
University of Chicago
Target Recruit Count
48
Registration Number
NCT07017478
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

Single Port Insufflation RCT

Not Applicable
Completed
Conditions
Postoperative Pain Score
First Posted Date
2025-05-25
Last Posted Date
2025-05-25
Lead Sponsor
University of Chicago
Target Recruit Count
70
Registration Number
NCT06990750
Locations
🇺🇸

The University of Chicago, Chicago, Illinois, United States

Tibial IMN Vs. Tibial Micromotion IMN

Not Applicable
Not yet recruiting
Conditions
Tibial Fracture
First Posted Date
2025-05-16
Last Posted Date
2025-05-16
Lead Sponsor
University of Chicago
Target Recruit Count
372
Registration Number
NCT06976801
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 174
  • Next

News

Sernova and Eledon Partner to Advance Type 1 Diabetes Bio-hybrid Organ Therapy with Novel Immunosuppression

Sernova Biotherapeutics and Eledon Pharmaceuticals announced a collaboration to evaluate tegoprubart, an anti-CD40L antibody, in Sernova's Phase 1/2 Cell Pouch Bio-hybrid Organ clinical trial for type 1 diabetes.

32 Biosciences Secures $6 Million Funding to Advance Gut Microbiome Diagnostic and Therapeutic Platform

32 Biosciences raised $6 million in funding to advance its AI-powered gut microbiome diagnostic platform and first-of-its-kind non-antibiotic antimicrobial therapy.

New Study Raises Safety Concerns About Fecal Microbiota Transplants

A new study published June 6, 2025, warns that fecal microbiota transplants may introduce microbes that hijack the host environment, potentially creating new health risks.

AB Science Secures Chinese Patent for Masitinib in COVID-19 Treatment Until 2041

AB Science has received a Chinese patent for its lead compound masitinib to treat COVID-19, providing intellectual property protection until April 2041.

ClostraBio Secures INVENT Illinois Funding, Appoints New CSO, and Prepares for Microbiome Therapeutic Launch

ClostraBio has secured new investment from the Illinois Innovation Venture Fund (INVENT) and NextGen Nutrition Investment Partners to advance its microbiome-focused therapeutics for gut health.

Weight Loss Drugs Wegovy and Zepbound Not Cost-Effective at Current Prices, Study Finds

Popular weight loss medications semaglutide (Wegovy) and tirzepatide (Zepbound) would need significant price reductions of 82% and 30% respectively to meet standard cost-effectiveness thresholds, according to new University of Chicago research.

Climate Change Extends Pollen Seasons, Prompting New Approaches to Allergy Management

Climate change has significantly extended pollen seasons across the United States, with western regions experiencing up to 20 additional freeze-free days, leading to prolonged allergy symptoms.

Radiation Oncology Pioneer Ralph Weichselbaum Named 2024 Giants of Cancer Care Inductee

Dr. Ralph R. Weichselbaum, chair of Radiation and Cellular Oncology at University of Chicago, has been named the 2024 Giants of Cancer Care inductee for his groundbreaking contributions to radiation oncology.

Dato-DXd Shows Promise in Previously Treated Advanced Non-Small Cell Lung Cancer

• Datopotamab deruxtecan (Dato-DXd) showed a numerical improvement in overall survival compared to docetaxel in previously treated advanced non-small cell lung cancer (NSCLC). • The TROPION-Lung01 trial highlighted a statistically significant improvement in progression-free survival in the nonsquamous NSCLC cohort treated with Dato-DXd. • A novel biomarker, TROP2 normalized membrane ratio (NMR), may predict outcomes to Dato-DXd, potentially refining patient selection. • Dato-DXd demonstrated a manageable safety profile with fewer dose reductions and treatment discontinuations compared to docetaxel.

Vertex's VX-880 Stem Cell Therapy Achieves Insulin Independence in Type 1 Diabetes Patients

Vertex Pharmaceuticals' VX-880 stem cell-derived islet cell therapy demonstrated remarkable efficacy in a Phase I/II trial, with all 12 full-dose patients achieving improved glycemic control and meeting ADA targets for HbA1c and time-in-range.

© Copyright 2025. All Rights Reserved by MedPath